November 17, 2015 (Shareholders Foundation) - An investigation on behalf of investors of Mallinckrodt PLC (NYSE:MNK) shares over potential securities laws violations by Mallinckrodt and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Mallinckrodt PLC (NYSE:MNK) concerning whether a series of statements by Mallinckrodt PLC regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Mallinckrodt PLC reported that its Total Revenue rose from over $2.02 billion for the 12 months period that ended on September 30, 2011 to over $2.54 billion for the 12 months period that ended on September 26, 2014 while its Net Income of $150.70 million for the 12 months period that ended on September 30, 2011 declined to a Net Loss of $319.30 million for the 12 months period that ended on September 26, 2014.

On November 9, 2015, Citron Research described Mallinckrodts abuse of the pharmaceutical reimbursement system, and stated that Mallinckrodt has significantly more downside than rival Valeant Pharmaceuticals International, Inc. and is a far worse offender of the reimbursement system.

Shares of Mallinckrodt PLC (NYSE:MNK) declined from $132.47 per share in March 2015 to as low as $52.01 per share on November 9, 2015.